http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Illumina to Announce Second Quarter 2022 Financial Results on Thursday, August 11, 2022
-
Illumina Among First in the World to Receive Approval of Science-Based Net-Zero Target
-
Pre-Open Movers: ironSource Surges on Buyback, Tech Stocks Fall on Hot CPI
-
Illumina Invests in £30M Venture Fund to Advance Breakthroughs in Human Health
-
Illumina (ILMN) Launches Research Test Codeveloped with Merck to Unlock Deeper Insights into the Tumor Genome
-
Illumina Launches Research Test Codeveloped with Merck to Unlock Deeper Insights into the Tumor Genome
-
Illumina (ILMN) Announces Joydeep Goswami Appointed Interim CFO; Sam Samad To Depart
-
JOYDEEP GOSWAMI APPOINTED INTERIM CFO; SAM SAMAD TO DEPART ILLUMINA
-
Illumina Announces Next Generation Products and Data at AGBT General Meeting to Advance Innovative Customer Solutions
-
Illumina to showcase the transformational impact of comprehensive genomic profiling in unlocking precision medicine for cancer patients, at ASCO
-
GRAIL (ILMN) Announces Collaboration With U.S. Department of Veterans Affairs and the Veterans Health Foundation to Evaluate Galleri® Multi-Cancer Early Detection Test
-
GRAIL Announces Collaboration With U.S. Department of Veterans Affairs and the Veterans Health Foundation to Evaluate Galleri® Multi-Cancer Early Detection Test
-
Senti Bio Secures Additional Financing from Leaps by Bayer and Provides Update on Proposed Business Combination with Dynamics Special Purpose Corp. (DYNS)
-
Illumina (ILMN) Introduces New Pan-Cancer Companion Diagnostic to Match Patients with Rare Genetic Mutations to Targeted Therapy
-
Illumina Introduces New Pan-Cancer Companion Diagnostic to Match Patients with Rare Genetic Mutations to Targeted Therapy
-
Illumina and Allegheny Health Network to Assess In-House Comprehensive Cancer Genomic Profiling to Enhance Patient Care
-
Illumina Reports Financial Results for First Quarter of Fiscal Year 2022
-
Illumina (ILMN) Partners with Deerfield Management to Accelerate Drug Development
-
Illumina and Deerfield Management partner to accelerate drug development
-
Illumina To Webcast Upcoming Investor Conference
-
Illumina Supports Leading German Hospital to Accelerate Genetic Disease Diagnosis in Critically Ill Children
-
PGA TOUR Champions and GRAIL Announce The Galleri® Classic
-
Illumina to Announce First Quarter 2022 Financial Results on Thursday, May 5, 2022
-
Illumina Expands Access to Genomics in Latin America through New State-of-the-Art Solution Center
-
John Frank Joins Illumina as Chief Public Affairs Officer
-
Illumina Releases Annual Corporate Social Responsibility Report
-
DNA Data Storage Alliance Welcomes 50th Member
-
Illumina Accelerator Invests in Seven Omics Startups Advancing Breakthrough Therapeutics, Diagnostics, DNA Storage, Mental Wellness, and Sustainable Foods Applications
-
Illumina (ILMN) Unveils Comprehensive Genomic Profiling Test for Cancer in Europe
-
Illumina Unveils Groundbreaking Comprehensive Genomic Profiling Test for Cancer in Europe
-
Illumina (ILMN) Appoints Carissa Rollins as Chief Information Officer
-
Illumina Welcomes Carissa Rollins as Chief Information Officer
-
Illumina To Webcast Upcoming Investor Conference
-
Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2021
-
Illumina To Webcast Upcoming Investor Conferences
-
Illumina (ILMN) Enters Partnerships in France for Precision Medicine Approach to Late-Stage Cancer
-
Illumina partners with centers across France to advance a precision medicine approach for patients with late-stage cancer
-
Illumina collaborates with National Cancer Center Japan to address a leading cause of death in Asia
-
Illumina to Announce Fourth Quarter & Full Year 2021 Financial Results on Thursday, February 10, 2022
-
Illumina collaborates with Nashville Biosciences to accelerate medicines development
-
Illumina (ILMN) announces preliminary consolidated fourth quarter revenue of approximately $1.19 billion
-
Illumina (ILMN) Enters Partnership with Boehringer Ingelheim for Diagnostic Programs
-
Illumina Partners with Agendia to Expand Genomic Testing in Breast Cancer Care
-
Illumina and Boehringer Ingelheim Announce Companion Diagnostic Partnership
-
Illumina delivers 2021 results ahead of expectations, strong 2022 guidance and deep pipeline of long-term growth opportunities at 2022 J.P. Morgan Healthcare Conference
-
GRAIL and Premier’s PINC AI™ Partner to Support Patient Access to Galleri® Multi-Cancer Early Detection Blood Test
-
Illumina Enters Co-Development Partnership with SomaLogic
-
Somalogic (SLGC) announces exclusive partnership with Illumina (ILMN) to develop sequencing-based proteomic solutions
-
Illumina To Webcast Upcoming Investor Conference
-
Senti Bio and Dynamics Special Purpose Corp. Announce Business Combination Agreement to Create Publicly Listed Company Pioneering Gene Circuit-Engineered Cell and Gene Therapies

